

ForPatients

by Roche

Hemophilia A

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN3)

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

Trial Status
Completed

Trial Runs In
14 Countries

Trial Identifier
NCT02847637 2016-000072-17,
HAVEN3 BH30071

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02847637 2016-000072-17, HAVEN3 BH30071
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥12 Years

Healthy Volunteers
No
